A story today at Newsday.com indicates the New Jersey Vioxx trial is still going well for the plaintiff. Of course Merck hasn’t begun to present their case, but if that presentation is as ineffective in New Jersey as it was in Texas, Merck is not going to overcome the plaintiff testimony.